Objective: To investigate the distribution of Chinese medicine (CM) syndrome in patients with acute myocardial infarction (AMI) on admission and its impact on prognosis. Methods: A total of 525 AMI patients were prosp...Objective: To investigate the distribution of Chinese medicine (CM) syndrome in patients with acute myocardial infarction (AMI) on admission and its impact on prognosis. Methods: A total of 525 AMI patients were prospectively recruited and classified into 4 groups based on their clinical characteristics: excess-heat, excess-cold, deficiency-heat and deficiency-cold syndromes. Major adverse cardiovascular events (MACEs) were followed up. Results: The excess syndrome was more common than deficiency syndrome (72.95% vs. 27.05%;P<0.05). Totally 495 (94.29%) of 525 AMI patients were followed up (median 277 days). There were 59 (11.92%) MACEs. After adjusted with confounding factors in Cox regression models, the hazard ratio (95% confidence interval) of excess-heat, excess-cold, deficiency-heat and deficiency-cold syndrome groups were 1, 1.25 (0.63, 2.49;P<0.05), 2.37 (1.14, 4.94;P<0.05), 3.76 (1.71, 8.28;P<0.05), respectively. Conclusions: Excess syndrome was more common in AMI patients and had better prognosis, while deficiency-cold syndrome had the poorest prognosis. CM syndrome was of value in predicting long-term outcomes in AMI patients.展开更多
Objective:To examine whether the combination of Naoxintong Capsule with standard care could further reduce the recurrence of ischemic stroke without increasing the risk of severe bleeding.Methods:A total of 23 Chinese...Objective:To examine whether the combination of Naoxintong Capsule with standard care could further reduce the recurrence of ischemic stroke without increasing the risk of severe bleeding.Methods:A total of 23 Chinese medical centers participated in this trial.Adult patients with a history of ischemic stroke were randomlyassigned ina 1:1ratiousing a blockdesign toreceive eitherNaoxintong Capsule(1.2gorally,twice a day)or placebo in addition to standard care.The primary endpoint was recurrence of ischemic stroke within 2 years.Secondary outcomes included myocardial infarction,death due to recurrent ischemic stroke,and all-cause mortality.The safety of drugs was monitored.Results were analyzed using the intention-to-treat principle.展开更多
基金Supported by the National Basic Research Program of China(No.2012CB518605)Science and Technology Innovative Program of Shanghai,China(No.10DZ1975400)
文摘Objective: To investigate the distribution of Chinese medicine (CM) syndrome in patients with acute myocardial infarction (AMI) on admission and its impact on prognosis. Methods: A total of 525 AMI patients were prospectively recruited and classified into 4 groups based on their clinical characteristics: excess-heat, excess-cold, deficiency-heat and deficiency-cold syndromes. Major adverse cardiovascular events (MACEs) were followed up. Results: The excess syndrome was more common than deficiency syndrome (72.95% vs. 27.05%;P<0.05). Totally 495 (94.29%) of 525 AMI patients were followed up (median 277 days). There were 59 (11.92%) MACEs. After adjusted with confounding factors in Cox regression models, the hazard ratio (95% confidence interval) of excess-heat, excess-cold, deficiency-heat and deficiency-cold syndrome groups were 1, 1.25 (0.63, 2.49;P<0.05), 2.37 (1.14, 4.94;P<0.05), 3.76 (1.71, 8.28;P<0.05), respectively. Conclusions: Excess syndrome was more common in AMI patients and had better prognosis, while deficiency-cold syndrome had the poorest prognosis. CM syndrome was of value in predicting long-term outcomes in AMI patients.
基金Supported by the Shanghai Municipal Commission of Science and Technology,China(No.STCSM 14401970300)。
文摘Objective:To examine whether the combination of Naoxintong Capsule with standard care could further reduce the recurrence of ischemic stroke without increasing the risk of severe bleeding.Methods:A total of 23 Chinese medical centers participated in this trial.Adult patients with a history of ischemic stroke were randomlyassigned ina 1:1ratiousing a blockdesign toreceive eitherNaoxintong Capsule(1.2gorally,twice a day)or placebo in addition to standard care.The primary endpoint was recurrence of ischemic stroke within 2 years.Secondary outcomes included myocardial infarction,death due to recurrent ischemic stroke,and all-cause mortality.The safety of drugs was monitored.Results were analyzed using the intention-to-treat principle.
